4基因风险评分模型的整合提高了急性髓性白血病的预后准确性
Yiqing Li1,2, Boqi Li3, Jie Xiao1,2
1Department of Hematology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
Cell cycle (Georgetown, Tex.)
|October 30, 2025
概括
一个新的四基因风险评分预测急性髓性白血病 (AML) 患者的整体存活率,有助于风险分层并确定AML治疗的潜在治疗点.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 急性髓性白血病 (AML) 呈现异质的临床结果.
- 患者复发是AML管理的一个重大挑战.
研究的目的:
- 开发AML复发和整体存活率 (OS) 的预测风险评分模型.
- 确定新的复发相关基因,用于AML的潜在治疗向.
主要方法:
- 来自GEO数据库的诊断和复发AML样本的差异基因表达分析.
- 考克斯回归分析将复发相关基因整合到风险得分模型中.
- 风险评分与欧洲白血病网 (ELN) 综合风险计划分类的整合.
主要成果:
- 四个基因 (SCN9A,CFH,CD34,CALCRL) 被确定为与复发相关的.
- 较高的风险得分与不利的ELN2017分类,白血病转变,FLT3-ITD和RUNX1突变相关.
- 较低的风险得分与NPM1突变有关,而较高的得分预测了较短的OS.
- 综合风险分类显示了明显不同的OS结果.
结论:
- 四基因风险评分有效预测AML患者的OS.
- 综合风险分类为AML结果提供了增强的预测潜力.
- 鉴定出来的基因可以作为AML治疗的潜在治疗点.
更多相关视频
08:31Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
553
07:13Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model
Published on: April 18, 2025
482
相关概念视频
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Cancer Survival Analysis
639
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
639
